Alpha2beta1 Integrin Polymorphism in Diffuse Astrocytoma Patients

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorTEIXEIRA, Silvia A.
dc.contributor.authorV, Regislaine Burim
dc.contributor.authorVIAPIANO, Mariano S.
dc.contributor.authorBIDINOTTO, Lucas T.
dc.contributor.authorMARIE, Suely K. Nagashi
dc.contributor.authorMALHEIROS, Suzana M. Fleury
dc.contributor.authorOBA-SHINJO, Sueli M.
dc.contributor.authorANDRADE, Augusto F.
dc.contributor.authorCARLOTTI, Carlos G.
dc.date.accessioned2022-10-26T14:31:09Z
dc.date.available2022-10-26T14:31:09Z
dc.date.issued2022
dc.description.abstractIntegrins are heterodimeric transmembrane glycoproteins resulting from the non-covalent association of an alpha and beta chain. The major integrin receptor for collagen/laminin, alpha 2 beta 1 is expressed on a wide variety of cell types and plays an essential role in the adhesion of normal and tumor cells to the extracellular matrix. Integrin-triggered signaling pathways promote the invasion and survival of glioma cells by modifying the brain microenvironment. In this study, we investigated the association of a specific genetic polymorphism of integrin alpha 2 beta 1 with the incidence of diffusely infiltrating astrocytoma and the progression of these tumors. Single-nucleotide polymorphism in intron 7 of the integrin ITGA2 gene was examined in 158 patients and 162 controls using polymerase chain reaction and restriction enzyme analysis. The ITGA2 genotype +/+ (with a BglII restriction site in both alleles) exhibited higher frequency in grade II astrocytoma compared to control (P = 0.02) whereas the genotype -/- (lacking the BglII site) correlated with the poorest survival rate (P = 0.04). In addition, in silico analyses of ITGA2 expression from low-grade gliomas (LGG, n = 515) and glioblastomas (GBM, n = 159) indicated that the higher expression of ITGA2 in LGG was associated with poor overall survival (P < 0.0001). However, the distribution of integrin ITGA2 BglII genotypes (+/+, +/-, -/-) was not significantly different between astrocytoma subgroups III and IV (P = 0.65, 0.24 and 0.33; 0.29, 0.48, 0.25, respectively) compared to control. These results suggest a narrow association between the presence of this SNP and indicate that further studies with larger samples are warranted to analyze the relation between tumor grade and overall survival, highlighting the importance of determining these polymorphisms for prognosis of astrocytomas.eng
dc.description.indexPubMedeng
dc.identifier.citationFRONTIERS IN ONCOLOGY, v.12, article ID 914156, 9p, 2022
dc.identifier.doi10.3389/fonc.2022.914156
dc.identifier.issn2234-943X
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/49263
dc.language.isoeng
dc.publisherFRONTIERS MEDIA SAeng
dc.relation.ispartofFrontiers in Oncology
dc.rightsopenAccesseng
dc.rights.holderCopyright FRONTIERS MEDIA SAeng
dc.subjectsingle nucleotide polymorphismeng
dc.subjectextracellular matrixeng
dc.subjectbrain microenvironmenteng
dc.subjecttumor progressioneng
dc.subjectlow grade gliomaeng
dc.subjectinvasioneng
dc.subjectITGA2eng
dc.subject.otherplatelet glycoprotein ia/iiaeng
dc.subject.other2 silent polymorphismseng
dc.subject.otheralpha(2) geneeng
dc.subject.othercell-adhesioneng
dc.subject.otherin-vitroeng
dc.subject.othermyocardial-infarctioneng
dc.subject.othertumor-cellseng
dc.subject.otheria geneeng
dc.subject.otherexpressioneng
dc.subject.othercancereng
dc.subject.wosOncologyeng
dc.titleAlpha2beta1 Integrin Polymorphism in Diffuse Astrocytoma Patientseng
dc.typearticleeng
dc.type.categoryoriginal articleeng
dc.type.versionpublishedVersioneng
dspace.entity.typePublication
hcfmusp.affiliation.countryEstados Unidos
hcfmusp.affiliation.countryCanadá
hcfmusp.affiliation.countryisous
hcfmusp.affiliation.countryisoca
hcfmusp.author.externalTEIXEIRA, Silvia A.:Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Surg & Anat, Sao Paulo, Brazil; Barretos Canc Hosp, Mol Oncol Res Ctr, Barretos, SP, Brazil
hcfmusp.author.externalV, Regislaine Burim:Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Surg & Anat, Sao Paulo, Brazil; Univ Sao Paulo, Fac Pharmaceut Sci Ribeirao Preto, Dept Clin Toxicol & Bromatol Anal, Sao Paulo, Brazil
hcfmusp.author.externalVIAPIANO, Mariano S.:Brigham & Womens Hosp, Dept Neurosurg, 75 Francis St, Boston, MA 02115 USA; Harvard Med Sch, Boston, MA 02115 USA; SUNY Upstate Med Univ, Dept Neurosci & Physiol, Syracuse, NY 13210 USA
hcfmusp.author.externalBIDINOTTO, Lucas T.:Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Surg & Anat, Sao Paulo, Brazil; UNESP Univ Estadual Paulista, Sch Med, Dept Pathol, Botucatu, SP, Brazil; Barretos Sch Hlth Sci, Dr Paulo Prata FACISB, Barretos, Brazil
hcfmusp.author.externalMALHEIROS, Suzana M. Fleury:Fed Univ Sao Paulo UNIFESP, Fac Med, Dept Neurol, Sao Paulo, Brazil
hcfmusp.author.externalANDRADE, Augusto F.:McGill Univ, Dept Human Genet, Montreal, PQ, Canada
hcfmusp.author.externalCARLOTTI, Carlos G.:Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Surg & Anat, Sao Paulo, Brazil
hcfmusp.citation.scopus0
hcfmusp.contributor.author-fmusphcSUELY KAZUE NAGAHASHI MARIE
hcfmusp.contributor.author-fmusphcSUELI MIEKO OBA SHINJO
hcfmusp.description.articlenumber914156
hcfmusp.description.volume12
hcfmusp.origemWOS
hcfmusp.origem.pubmed35936750
hcfmusp.origem.scopus2-s2.0-85135487588
hcfmusp.origem.wosWOS:000837085000001
hcfmusp.publisher.cityLAUSANNEeng
hcfmusp.publisher.countrySWITZERLANDeng
hcfmusp.relation.referenceAdorno-Cruz V, 2021, GENES DIS, V8, P493, DOI 10.1016/j.gendis.2020.01.015eng
hcfmusp.relation.referenceArsene S, 2011, THROMB RES, V128, P293, DOI 10.1016/j.thromres.2011.05.009eng
hcfmusp.relation.referenceAyala F, 2003, BREAST CANCER RES TR, V80, P145, DOI 10.1023/A:1024598732178eng
hcfmusp.relation.referenceCarlsson LE, 1999, BLOOD, V93, P3583, DOI 10.1182/blood.V93.11.3583.410k34_3583_3586eng
hcfmusp.relation.referenceCasorelli I, 2001, BRIT J HAEMATOL, V114, P150, DOI 10.1046/j.1365-2141.2001.02868.xeng
hcfmusp.relation.referenceCeccarelli M, 2016, CELL, V164, P550, DOI 10.1016/j.cell.2015.12.028eng
hcfmusp.relation.referenceChamberlain MC, 2012, EXPERT REV NEUROTHER, V12, P421, DOI [10.1586/ern.11.188, 10.1586/ERN.11.188]eng
hcfmusp.relation.referenceChin SP, 2015, PROSTATE, V75, P723, DOI 10.1002/pros.22954eng
hcfmusp.relation.referenceChuang YC, 2018, BIOL PROCED ONLINE, V10, DOI 10.1186/s12575-018-0073-xeng
hcfmusp.relation.referenceCorral J, 1999, THROMB HAEMOSTASIS, V81, P951, DOI 10.1055/s-0037-1614605eng
hcfmusp.relation.referenceDanen E.H., 2013, ISRN CELL BIOL, V2013, P135164, DOI [10.1155/2013/135164, DOI 10.1155/2013/135164]eng
hcfmusp.relation.referenceDardik R, 1997, INT J CANCER, V70, P201, DOI 10.1002/(SICI)1097-0215(19970117)70:2<201::AID-IJC11>3.0.CO;2-Leng
hcfmusp.relation.referenceDelamarre E, 2009, AM J PATHOL, V175, P844, DOI 10.2353/ajpath.2009.080920eng
hcfmusp.relation.referenceDi Paola J, 2005, J THROMB HAEMOST, V3, P1511, DOI 10.1111/j.1538-7836.2005.01273.xeng
hcfmusp.relation.referenceDing W, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135128eng
hcfmusp.relation.referenceEllert-Miklaszewska A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21030888eng
hcfmusp.relation.referenceFerraro A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115276eng
hcfmusp.relation.referenceFriedl P, 2003, BIOCHEM SOC SYMP, V70, P277, DOI 10.1042/bss0700277eng
hcfmusp.relation.referenceFriedlander DR, 1996, CANCER RES, V56, P1939eng
hcfmusp.relation.referenceGINGRAS MC, 1995, J NEUROIMMUNOL, V57, P143, DOI 10.1016/0165-5728(94)00178-Qeng
hcfmusp.relation.referenceGirotti MR, 2011, J INVEST DERMATOL, V131, P2438, DOI 10.1038/jid.2011.239eng
hcfmusp.relation.referenceGROSSI IM, 1988, FASEB J, V2, P2385, DOI 10.1096/fasebj.2.8.2452113eng
hcfmusp.relation.referenceGrzesiak JJ, 2006, BRIT J CANCER, V94, P1311, DOI 10.1038/sj.bjc.6603088eng
hcfmusp.relation.referenceGui GPH, 1997, BRIT J CANCER, V75, P623, DOI 10.1038/bjc.1997.113eng
hcfmusp.relation.referenceGuo P, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-42643-7eng
hcfmusp.relation.referenceHuang CW, 2011, J NUCL MED, V52, P1979, DOI 10.2967/jnumed.111.091256eng
hcfmusp.relation.referenceHYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-Seng
hcfmusp.relation.referenceIhnatko R, 2006, INT J ONCOL, V29, P1025eng
hcfmusp.relation.referenceKAMATA T, 1994, J BIOL CHEM, V269, P9659eng
hcfmusp.relation.referenceKritzik M, 1998, BLOOD, V92, P2382, DOI 10.1182/blood.V92.7.2382eng
hcfmusp.relation.referenceKunicki TJ, 1997, BLOOD, V89, P1939, DOI 10.1182/blood.V89.6.1939eng
hcfmusp.relation.referenceLei X, 2020, CANCER LETT, V470, P126, DOI 10.1016/j.canlet.2019.11.009eng
hcfmusp.relation.referenceLin L, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.738651eng
hcfmusp.relation.referenceLiu CZ, 2006, J PHARMACOL SCI, V101, P103, DOI 10.1254/jphs.SC0050174eng
hcfmusp.relation.referenceLouis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1eng
hcfmusp.relation.referenceMadamanchi A, 2014, ADV EXP MED BIOL, V819, P41, DOI 10.1007/978-94-017-9153-3_3eng
hcfmusp.relation.referenceMahesparan R, 2003, ACTA NEUROPATHOL, V105, P49, DOI 10.1007/s00401-002-0610-0eng
hcfmusp.relation.referenceMatsubara Y, 2000, BLOOD, V95, P1560, DOI 10.1182/blood.V95.5.1560.005k43_1560_1564eng
hcfmusp.relation.referenceMeldolesi J, 2016, PHARMACOL RES, V107, P430, DOI 10.1016/j.phrs.2015.10.019eng
hcfmusp.relation.referenceMiyake K, 2000, J NEUROPATH EXP NEUR, V59, P18, DOI 10.1093/jnen/59.1.18eng
hcfmusp.relation.referenceMoshfegh K, 1999, LANCET, V353, P351, DOI 10.1016/S0140-6736(98)06448-4eng
hcfmusp.relation.referenceNaci D, 2015, SEMIN CANCER BIOL, V35, P145, DOI 10.1016/j.semcancer.2015.08.004eng
hcfmusp.relation.referenceNIERODZIK ML, 1995, THROMB HAEMOSTASIS, V74, P282eng
hcfmusp.relation.referenceNoushmehr H, 2010, CANCER CELL, V17, P510, DOI 10.1016/j.ccr.2010.03.017eng
hcfmusp.relation.referenceOhgaki H, 2013, CLIN CANCER RES, V19, P764, DOI 10.1158/1078-0432.CCR-12-3002eng
hcfmusp.relation.referenceOjalill Marjaana, 2018, Oncotarget, V9, P32435, DOI 10.18632/oncotarget.25945eng
hcfmusp.relation.referencePaolillo M, 2016, PHARMACOL RES, V113, P55, DOI 10.1016/j.phrs.2016.08.004eng
hcfmusp.relation.referencePaulus W, 1996, LAB INVEST, V75, P819eng
hcfmusp.relation.referencePoglajen G, 2004, FOLIA BIOL-PRAGUE, V50, P203eng
hcfmusp.relation.referenceQuader S, 2017, J CONTROL RELEASE, V258, P56, DOI 10.1016/j.jconrel.2017.04.033eng
hcfmusp.relation.referenceRen DY, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1496-1eng
hcfmusp.relation.referenceRinger P, 2017, MATRIX BIOL, V64, P6, DOI 10.1016/j.matbio.2017.03.004eng
hcfmusp.relation.referenceRooprai HK, 1999, INT J DEV NEUROSCI, V17, P613, DOI 10.1016/S0736-5748(99)00051-9eng
hcfmusp.relation.referenceRuiz-Ontanon P, 2013, STEM CELLS, V31, P1075, DOI 10.1002/stem.1349eng
hcfmusp.relation.referenceSalemi Z, 2021, J CELL PHYSIOL, V236, P4954, DOI 10.1002/jcp.30202eng
hcfmusp.relation.referenceSamur MK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106397eng
hcfmusp.relation.referenceSelistre-de-Araujo HS, 2005, BRAZ J MED BIOL RES, V38, P1505, DOI 10.1590/S0100-879X2005001000007eng
hcfmusp.relation.referenceStupp R, 2009, ANN ONCOL, V20, P126, DOI 10.1093/annonc/mdp151eng
hcfmusp.relation.referenceSu CY, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.579068eng
hcfmusp.relation.referenceTAKADA Y, 1989, EMBO J, V8, P1361, DOI 10.1002/j.1460-2075.1989.tb03516.xeng
hcfmusp.relation.referenceTeodorczyk M, 2010, J CELL PHYSIOL, V222, P1, DOI 10.1002/jcp.21901eng
hcfmusp.relation.referenceTran T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026858eng
hcfmusp.relation.referenceUematsu T, 2012, J CELL PHYSIOL, V227, P3072, DOI 10.1002/jcp.23054eng
hcfmusp.relation.referenceUhm Joon H., 1999, Frontiers in Bioscience, V4, pD188, DOI 10.2741/Uhmeng
hcfmusp.relation.referenceVairaktaris E, 2006, EJSO-EUR J SURG ONC, V32, P455, DOI 10.1016/j.ejso.2005.12.005eng
hcfmusp.relation.referenceVan de Walle GR, 2005, J BIOL CHEM, V280, P36873, DOI 10.1074/jbc.M508148200eng
hcfmusp.relation.referenceVerhoeff TJ, 2022, BREAST CANCER RES TR, V192, P89, DOI 10.1007/s10549-021-06496-xeng
hcfmusp.relation.referenceWadajkar AS, 2017, WIRES NANOMED NANOBI, V9, DOI 10.1002/wnan.1439eng
hcfmusp.relation.referenceWafai R, 2020, BREAST CANCER RES, V22, DOI 10.1186/s13058-020-01366-8eng
hcfmusp.relation.referenceWang LM, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12835eng
hcfmusp.relation.referenceYilmaz U, 2013, ASIAN PAC J CANCER P, V14, P5929, DOI 10.7314/APJCP.2013.14.10.5929eng
hcfmusp.relation.referenceZhang X, 2012, EXP THER MED, V3, P9, DOI 10.3892/etm.2011.367eng
hcfmusp.scopus.lastupdate2024-05-10
relation.isAuthorOfPublication97df2bf7-eb85-4fff-a1dc-d2d1fe781489
relation.isAuthorOfPublication6db493d7-f88b-41d2-bdf6-ff0ffaa44a54
relation.isAuthorOfPublication.latestForDiscovery97df2bf7-eb85-4fff-a1dc-d2d1fe781489
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
art_TEIXEIRA_Alpha2beta1_Integrin_Polymorphism_in_Diffuse_Astrocytoma_Patients_2022.PDF
Tamanho:
2.14 MB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - FM/MNE
Artigos e Materiais de Revistas Científicas - LIM/15
Artigos e Materiais de Revistas Científicas - ODS/03